| 영문 | platelet | 한글 | 혈소판 |
|---|---|---|---|
| 설명 | 골수의 거대 세포인 거대핵세포의 세포질 일부가 떨어져서 순환 혈액 중에 출현한 것으로 직경이 2~4μm의 작은 과립체이다. 혈소판은 손상을 입은 혈관의 노출된 결합 조직에 붙어 여러 물질을 분비하여 지혈 및 혈액 응고에 중요한 역할을 한다. |
||
| PA | panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'... |
|---|---|
| MAOI | MonoAmine Oxidase Inhibitors |
| PAFI | platelet-aggregation factor inhibitor |
| PAT | Pain Apperception Test; paroxysmal atrial tachycardia; patient; phenylaminotetrazole; physical abili... |
| SPA | salt-poor albumin; sheep pulmonary adenomatosis; sperm penetration assay; spinal progressive amyotro... |
| PA | Platelet aggregation |
|---|---|
| PAT | Platelet aggregation test |
| RIPA | Ristocetin induced platelet aggregation |
| SIPA | Sh ear-induced platelet aggregation |
| SPA | Spontaneous Platelet Aggregation |
| platelet aggregation inhibitors | Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (12 Dec 1998) |
|---|
| platelet aggregation | The attachment of platelets to one another. This clumping together can be induced by a number of agents (e.g., thrombin, collagen) and is part of the mechanism leading to the formation of a thrombus. (12 Dec 1998) |
|---|---|
| platelet aggregation test | A test of the ability of platelets to adhere to each other and hence form a haemostatic plug to prevent bleeding; failure to aggregate occurs in several conditions, e.g., thrombasthenia, Von Willebrand's disease, and following administration of aspirin, phenylbutazone, and indomethacin; the test is conducted by quantitating the decrease in turbidity that occurs in platelet-rich plasma following the in vitro addition of one or several platelet-aggregating agents (e.g., ADP, epinephrine, or serotonin). (05 Mar 2000) |
| aggregation | Massing of materials together as in clumping. (18 Nov 1997) |
| receptor aggregation | Chemically stimulated aggregation of cell surface receptors, which potentiates the action of the effector cell. (12 Dec 1998) |
| cell aggregation | The phenomenon by which dissociated cells intermixed in vitro tend to group themselves with cells of their own type. (12 Dec 1998) |
| erythrocyte aggregation | Aggregation of erythrocytes probably resulting from changes in the negative surface charge (zeta potential) of the cells caused by the dielectric effect of proteins in the surrounding plasma, especially asymmetric macromolecules like fibrinogen and gamma-globulin. (12 Dec 1998) |
| erythrocyte aggregation, intravascular | The massing or clumping of erythrocytes in intact blood vessels in response to injury or in certain diseases, interfering with adequate blood flow. It is also called sludging of blood and intravascular agglutination. (12 Dec 1998) |
| familial aggregation | <genetics> The occurrence of a trait in more members of a family than can be readily accounted for by chance; presumptive but not cogent evidence of the operation of genetic factors. (05 Mar 2000) |
| adrenergic uptake inhibitors | Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (antidepressive agents, tricyclic) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (12 Dec 1998) |
| blood coagulation factor inhibitors | Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria. (12 Dec 1998) |
| Bowman Birk protease inhibitors | <pharmacology> Family of serine protease inhibitors found in seeds of leguminous plants and cereals. (18 Nov 1997) |
| carbonic anhydrase inhibitors | A class of compounds that reduces the secretion of h+ ions by the proximal kidney tubule through inhibition of carbonic anhydrase (carbonate dehydratase). Although their therapeutic use as diuretics is not frequent, they are used in clinical conditions where alkalinization of the urine is beneficial. Their most frequent application is in the reduction of intra-ocular pressure in the treatment of glaucoma. (12 Dec 1998) |
| reverse transcriptase inhibitors | Inhibitors of reverse transcriptase (RNA-directed DNA polymerase), an enzyme that synthesises DNA on an RNA template. (12 Dec 1998) |
| growth inhibitors | Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= plant growth regulators). (12 Dec 1998) |
| phosphodiesterase inhibitors | Compounds which inhibit or antagonise the biosynthesis or actions of phosphodiesterases. (12 Dec 1998) |
Synonyms : Antiplatelet Drugs, Blood Platelet Aggregation Inhibitors, Blood Platelet Antagonists, Blood Platelet Antiaggregants, Platelet Inhibitors, Agents, Antiplatelet, Aggregation Inhibitors, Platelet, Antagonists, Blood Platelet, Antagonists, Platelet
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|